Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Discovery Provides Insight into Fundamental Mystery of Fetal-Maternal Immune Tolerance

By LabMedica International staff writers
Posted on 21 Jun 2012
Scientists for the first time have discovered key steps in the molecular mechanisms involved in preventing the immune system of pregnant mammals from rejecting fetal tissue as foreign. More...
The findings may also provide leads to better understanding and treatment of medical conditions arising from abnormalities in this and similar immune system pathways.

Although the foreign antigens of the developing fetus and of the placenta come into direct contact with cells of the maternal immune system, they fail to evoke the typical rejection response seen with organ transplant tissue and pathogens. Previous findings by researchers at New York University School of Medicine (New York City, NY, USA) prompted them to ask if there was some sort of barrier preventing activated T cells from reaching the fetus. They turned their attention to studying properties of the decidua and there, in a mouse model, they found new answers. The research team has now discovered that the onset of pregnancy causes the genes responsible for recruiting immune cells to sites of inflammation to be turned off within the decidua. As a result, T cells are not able to accumulate inside the decidua and therefore do not attack the fetus and placenta. Specifically, the implantation of an embryo changes the packaging of certain chemokine genes in the nuclei of the developing decidua's stromal cells. The change in the DNA packaging permanently silences (deactivates) the chemokine genes. Consequently, the chemokines are not expressed and T cells are not recruited to the site of embryo implantation.

Also of note, the observed change in the DNA packaging occurred by epigenetic modification, a modification that changes gene expression but not due to a hereditable gene mutation. So the findings also reveal “epigenetic modification of chemokine genes within tissue stromal cells as a modality for limiting the trafficking of activated T cells," said lead investigator Adrian Erlebacher, MD, PhD, associate professor of pathology at NYU School of Medicine and member of the NYU Cancer Institute at NYU Langone Medical Center. "It turns out that the cells that typically secrete the chemoattractants to bring the T cells to sites of inflammation are inhibited from doing so in the context of the pregnant uterus. The decidua appears instead as a zone of relative immunological inactivity," he explained.

Prof. Erlebacher and his team will next investigate whether these modifications are also present within the human decidua and whether the failure to generate them appropriately is associated with complications of human pregnancy. In addition to pregnancy, the study’s findings could also have medical implications for organ transplantation, autoimmune diseases, and even cancer since they also raise the possibility that the same kind of mechanism could enhance a tumor's ability to survive inside its host.

Related Links:
New York University School of Medicine


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.